TORONTO, September 30, 2021 / PRNewswire / – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for people with depression and related disorders, is pleased to report encouraging preliminary results from a recent clinical study which suggest that ketamine may be as effective as a stand-alone antidepressant, compared to adjunct therapy.
The study, which was conducted at the Canadian Center of Excellence for Rapid Treatment (CRTCE), a wholly owned subsidiary of Braxia, showed comparable clinical benefits (e.g. depression (TRD) who received intravenous (IV) infusions ) ketamine monotherapy, compared to those receiving IV ketamine in addition to oral antidepressants.
Following the study protocols, participants in the ketamine monotherapy group achieved response and remission rates of 39.1% and 17.4%, respectively. Meanwhile, people receiving ketamine treatment in addition to antidepressants recorded corresponding rates of 21.9% and 6.7%.
“We continue to inform and refine treatment protocols on the implementation of ketamine for people with DRT,” said Dr. Roger mcintyre, CEO, Braxia Scientific. “In many circumstances, people who have safely received ketamine treatment have been able to discontinue their ineffective conventional treatments and switch entirely to ketamine monotherapy. Additionally, this data further informs Braxia Scientific’s drug discovery and development, particularly with respect to selection and registration for our clinical research studies.
“Ketamine has been shown to provide rapid and significant antidepressant effects in people with unipolar and bipolar TDR, and can also quickly reduce suicidal thoughts,” said Dr. Joshua Rosenblat, Medical and Scientific Director of Braxia Scientific. “Although these results are preliminary, they support the idea that ketamine is a very effective, rapid-acting antidepressant treatment approach, as evidenced by its ability to improve depression as monotherapy. These data are particularly important because they show that the benefits of ketamine may not depend on co-prescribing other drugs.
According to the study, “Ketamine has been almost exclusively studied as a supplemental antidepressant to other antidepressants. Due to the lack of high-quality clinical data on the safety and efficacy of ketamine as a monotherapy antidepressant, the majority of clinicians continue to prescribe ketamine. to patients provided they remain on a stable dose of one or more antidepressant drugs for the duration of treatment. “
Dr Rosenblat added, “The study provides real-world evidence, from a large sample of people seeking treatment for TRD, that advance science and corroborate our research that ketamine is a safe treatment, effective and fast-acting for depression, suicidality and other brain disorders. “
About Braxia Scientific Corp.
Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for people with depression and related disorders. Through its medical solutions, Braxia aims to reduce the disease burden of brain-related mental disorders such as major depressive disorder, among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, treatment of mental health disorders, and (ii) research activities related to the discovery and commercialization of new drugs and delivery methods. . Braxia is looking to develop ketamine and derivatives and other psychedelics from its IP development platform. Through its wholly owned subsidiary, the Canadian Center of Excellence for Rapid Treatment Inc., Braxia currently operates multidisciplinary community clinics providing rapid-acting treatments for depression located in Mississauga, Toronto, Ottawa, and Montreal.
ON BEHALF OF THE BOARD
“Dr. Roger S. McIntyre“
Dr. Roger S. McIntyre
Chairman and CEO
The CSE has not reviewed and accepts no responsibility for the accuracy or relevance of this release.
Caution regarding forward-looking information
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance are “forward-looking statements”.
Forward-looking statements include statements about the promise of ketamine-based treatments for depression and the potential of ketamine to treat other emerging psychiatric disorders, such as bipolar depression. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to differ materially from the future results, events or developments expressed or implied by such forward-looking statements. These risks and uncertainties include, among others, the inability of ketamine, psilocybin and other psychedelics to provide the expected health benefits and unintended side effects, dependence on obtaining and using maintenance of regulatory approvals, including the acquisition and renewal of federal, provincial, municipal, local or other approvals. licenses and engage in activities that may later be deemed illegal under national or international law. Ketamine and psilocybin are currently scheduled substances in Schedule I and Schedule III, respectively, under the Controlled Drugs and Substances Act, SC 1996, c. 19 (the “CDSA”) and possession of such substances under the CDSA without a prescription or statutory exemption constitutes a criminal offense. Health Canada has not approved psilocybin as a drug for any indication, however ketamine is a legally licensed drug for the treatment of certain psychological conditions. It is illegal to possess such substances in Canada without a prescription.
These factors should be carefully considered and readers are cautioned not to place undue reliance on these forward-looking statements.
Although the Company has attempted to identify material risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actual actions to differ from those described in forward-looking statements. actions, events or results differ from those anticipated, estimated or predicted. Additional information identifying the risks and uncertainties that could affect the financial results is contained in the documents filed by the Company with the Canadian securities regulators, including the amended and restated registration statement dated April 15, 2021, which are available at www.sedar.com. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.
View original content to download multimedia: https://www.prnewswire.com/news-releases/braxia-scientific-reports-encouraging-results-of-ketamine-study-showing-significant-reduction-in-depressive-symptoms -and -suicidality-with-ketamine-as-treatment-solo-301388447.html
SOURCE Braxia Scientific Corp.